HIV Treatment
UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall
- Details
- Category: HIV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by UNAIDS
The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade. 
Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs
- Details
- Category: Search for a Cure
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
An experimental gene therapy technique that modifies CD4 T-cells to protect them from viral entry produced lasting CD4 cell increases with a single infusion, as well as reduction in proviral DNA reservoirs and decreased viral load in 2 patients who underwent antiretroviral therapy (ART) interruption, according to data presented this week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City.
Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions
- Details
- Category: HIV Treatment Guidelines
- Published on Thursday, 09 May 2013 00:00
- Written by Liz Highleyman
On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of Americaannounced the release of revised Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, updating the previous version from 2009.
Very Early Antiretroviral Therapy Does Not Prevent Immune Activation
- Details
- Category: Search for a Cure
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
People who started antiretroviral therapy (ART) during acute HIV infection and experienced sustained viral suppression saw a substantial decrease in immune activation markers on their CD8 T-cells after 2 years of treatment, but often not to the level seen in HIV negative individuals, according to a report in the April 15, 2013, Journal of Acquired Immune Deficiency Syndromes.
Efavirenz More Effective than Nevirapine for Children with HIV
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 09 May 2013 00:00
- Written by Children’s Hospital of Philadelphia
HIV positive African children and adolescents treated with efavirenz (Sustiva) were less likely to experience virological failure than those using nevirapine (Viramune), according to a large comparative study published in the May 1, 2013, Journal of the American Medical Association. Nevirapine, however, is less expensive and more widely available for children in low-income countries.
More Articles...
- FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds
- FDA Approves Efavirenz (Sustiva) for HIV+ Children Ages 3 Months to 3 Years
- Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir
- Antiretroviral Therapy May Have Protective Effect on HIV+ Children's Hearts
Web Design and Development by